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ABSTRACT 
Barrett's oesophagus is the major risk factor for oesophageal adenocarcinoma. The management of 
Barrett’s oesophagus entails treating reflux symptoms with acid-suppressing medication or surgery 
(fundoplication). However neither form of anti-reflux therapy produces predictable regression, or 
prevents cancer development. Patients with Barrett’s oesophagus usually undergo endoscopic 
surveillance which aims to identify dysplastic changes or cancer at its earliest stage, when treatment 
outcomes should be better. Alternative endoscopic interventions are now available and are 
suggested for the treatment of early cancer, and prevention of progression of Barrett’s oesophagus 
to cancer. Such treatments could minimize the risks associated with oesophagectomy. The current 
status of these interventions is reviewed. 
 
Various endoscopic interventions have been described, but with long term outcomes uncertain, they 
remain somewhat controversial. Radiofrequency ablation (RFA) of dysplastic Barrett’s oesophagus 
might reduce the risk of cancer progression, although cancer development has been reported after 
this treatment. Endoscopic mucosal resection (EMR) allows a 1.5 to 2 cm diameter piece of 
oesophageal mucosa to be removed. This provides better pathology for diagnosis and staging, and if 
the lesion is confined to the mucosa and fully excised, EMR can be curative. The combination of 
EMR and RFA has been used for multifocal lesions, but long term outcomes are unknown. The new 
endoscopic interventions for Barrett’s oesophagus and early oesophageal cancer have potential to 
improve clinical outcomes, although evidence which confirms superiority over oesphagectomy is 
limited. Longer term outcome data and data from larger cohorts is required to confirm the 
appropriateness of these procedures. 
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Introduction 
 
Barrett's oesophagus is an adaptive response to repeated episodes of reflux of gastric contents into 
the oesophageal lumen, following which the mucosa in the distal oesophagus undergoes metaplastic 
change from squamous to a columnar mucosa. A recent study estimates that this condition probably 
affects 5.6% of the population in the USA 1. In the Western World the incidence appears to be 
increasing 2, and this is important because Barrett's oesophagus is the major risk factor for the 
development of oesophageal adenocarcinoma. Patients with Barrett's oesophagus carry a risk of 
oesophageal adenocarcinoma that is 30-125 times higher than that of an age-matched population 3, 
and the annual risk of this cancer developing in Barrett’s oesophagus is reported to be from 0.2% to 
2.1% 4. In addition, the incidence of oesophageal adenocarcinoma in Europe 5, North America 6, 
and Australia 7 is increasing at a rate exceeding that of any other cancer, with a near 6 fold increase 
over the last 3 to 4 decades, predominantly in men. The prognosis for this cancer is poor and 
approximately 90% of sufferers will die from this disease. This is because potentially curative 
treatment, usually oesophagectomy, is only feasible in approximately 25-30% of individuals, and 
surgical treatment is associated with significant morbidity and mortality.  
 
At present, the management of Barrett’s oesophagus entails treating reflux with acid-suppressing 
medication (usually a proton pump inhibitor (PPI)) or surgery (fundoplication), followed by regular 
endoscopic surveillance. Whilst there have been isolated reports of Barrett’s oesophagus regressing 
following medical therapy 8 and fundoplication 9,10, neither produces predictable regression, or 
prevents cancer development 11. Oesophagectomy for Barrett’s oesophagus in the absence of 
adenocarcinoma is not recommended, except in “fit” patients who progress to high grade dysplasia 
(HGD), the stage before invasive cancer, although even this is controversial as there is only a 
limited understanding of the natural history of HGD 12. Hence, alternative endoscopic interventions 
for early stage disease could minimize the morbidity and mortality associated with 
oesophagectomy, and might improve outcomes. Over the last 2 decades various endoscopic 
interventions have been described, although their place in the treatment spectrum still remains 
somewhat controversial. In this paper, the current status of endoscopic interventions for HGD and 
early cancer arising in Barrett’s oesophagus is reviewed. 
 
Endoscopic Ablation of Barrett’s oesophagus 
Various endoscopic techniques have been investigated for eradicating Barrett’s oesophagus 
epithelium, in particular dysplastic epithelium.  Both focal ablation techniques (argon plasma 
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coagulation (APC), multipolar electrocoagulation, laser heater probe, and endoscopic mucosal 
resection (EMR)) and field ablation techniques (photodynamic therapy (PDT) and radiofrequency 
ablation (RFA)) 13 have been used to ablate dysplastic and non-dysplastic Barrett’s oesophagus 
mucosa. The destruction of metaplastic columnar mucosa in an acid free environment is usually 
followed by regeneration with a squamous mucosa, irrespective of the method used. If applied to 
treatment of cancer or HGD, the goal of therapy should be to remove any target lesion, and to ablate 
all intestinal metaplasia (both dysplastic and non-dysplastic) to eliminate the risk of recurrence in 
the remaining Barrett’s oesophagus segment 14, 15.  
 
In most patients, new squamous mucosa formed after ablation (neosquamous mucosa) has a 
histopathological structure which is similar to that of normal oesophageal mucosa16. Whilst it is 
hoped that the neosquamous mucosa has a reduced cancer risk, the evidence supporting this is 
currently limited. Even if the risk is reduced, there remains the potential for malignancy to arise in 
islands of retained columnar mucosa or in buried areas of columnar mucosa lying underneath 
neosquamous mucosa. Cancer may also arise from within regenerated neosquamous mucosa, as this 
mucosa has not yet been shown to be stable. There has been a case report of cancer arising in 
neosquamous mucosa 17, and there have been reports of HGD and oesophageal adenocarcinoma 
developing following an endoscopically assessed 100% complete eradication response to ablation 
18, 19. The questions that should be asked therefore are; does ablation reduce or eliminate the risk of 
cancer, and which technique is most effective and/or cost effective? 
 
Photodynamic therapy  
Photodynamic therapy (PDT) entails administering a photosensitizing drug which sensitizes tissue 
to specific wavelengths of light. Non-thermal light of the appropriate wavelength delivered via an 
endoscope activates the photosensitizer, and this results in mucosal injury. It is thus a field ablation 
technique which can achieve circumferential ablation over a 3-7cm segment length. PDT ablation 
achieves complete reversion of columnar to squamous epithelium in 50-90% of treated patients 20, 
21, although it is associated with morbidity including chest pain and odynophagia 22, 
photosensitivity, and up 36% of treated patients will develop a post-treatment oesophageal stricture 
23. 
 
In 2005 Overholt et al reported a trial of PDT ablation vs. surveillance in patients with HGD 24. 
Although this trial showed less progression to cancer at 5 yrs following PDT (21/136 vs. 20/70), the 
progression rate after PDT was still 15% 23, indicating that the risk of cancer was only halved. 
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Follow-up in this study was incomplete, and in 1/3 of patients PDT was followed by an oesophageal 
stricture which required endoscopic dilatation. Nevertheless, this trial provided evidence that the 
risk of malignancy arising in dysplastic Barrett’s oesophagus might be reduced by endoscopic 
ablation. It remains, however, the only randomized trial to evaluate PDT for the prevention of 
cancer, and one of the few randomized trials in this area. PDT has largely been replaced by other 
cheaper and more widely available ablation methods, and it is no longer available in Australia or 
New Zealand. 
 
Argon Plasma Coagulation (APC)  
Argon Plasma Coagulation (APC) ablation uses monopolar electrocautery, via a stream of argon 
gas plasma which carries an electrical charge through to the closest mucosal surface, allowing 
ablation without direct contact. APC ablation is associated with a low incidence of post-procedural 
problems, and it is relatively inexpensive. At short term follow-up, APC has been shown to be 
reasonably effective for ablation of non-dysplastic Barrett’s oesophagus. Van Laethem et al 25 
reported that 25 of 31 patients (81%) taking 40mg of omeprazole daily had complete endoscopic 
regression of their Barrett’s oesophagus one month after APC treatment, although this decreased to 
61% when buried Barrett’s glands discovered on endoscopic biopsy were added to the data analysis. 
The significance of buried glands is uncertain but does sound a note of caution as to the need for 
ongoing surveillance. Similarly, when using both histopathological and endoscopic assessment 
criteria, Kahaleh et al 26 reported only 22 of 39 (56%) patients, using 20-40mg omeprazole per day, 
had complete eradication of Barrett’s oesophagus with APC at 1 month . Basu et al 27 found in a 
study of 50 patients with medically controlled reflux and a mean 5.9 cm length of Barrett’s 
oesophagus,  greater than 90% of Barrett’s oesophageal mucosa was eradicated in only 68% of 
patients. With very high dose PPI therapy (120mg omeprazole daily) at the time of ablation, and 
high power APC (90W), Madisch et al 28 reported 70 patients with initial 100% complete Barrett’s 
oesophagus ablation, but a subsequent histopathological relapse rate of 3% per year.  
 
Trials of Barrett’s oesophagus ablation in patients who had undergone previous antireflux surgery 
to control reflux are few and involve small patient numbers. Pinotti et al 29 enrolled 19 patients at 
least 2 months following laparoscopic Nissen fundoplication and reported 100% success for the 
elimination of Barrett’s oesophagus with APC treatment. Similarly Ferraris et al 30 completely 
eradicated the Barrett’s oesophagus mucosa in 46 post-fundoplication patients. Morino et al 31 
observed histopathologically complete squamous re-epithelialisation in 20 of 23 patients treated 
with APC after laparoscopic fundoplication. 
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We enrolled 126 patients with non-dysplastic Barrett’s oesophagus or low grade dysplasia (LGD) 
into 2 randomised controlled trials evaluating APC ablation vs. endoscopy surveillance 10, 32, 33. In 
these trials 95-100% macroscopic (endoscopic) ablation was achieved after 2-6 treatment sessions, 
and outcome data suggested a more durable response in patients who had undergone antireflux 
surgery compared with patients whose acid reflux was managed with proton pump inhibitor 
medication 32, 33. In patients who underwent ablation after fundoplication, a stable neosquamous 
epithelium was confirmed 5 years post-ablation by both endoscopic and histopathological criteria, 
with no progression to cancer or high grade dysplasia 10. In addition, during 5 year follow-up, 3 
control (surveillance only) patients within the post-fundoplication trial progressed to dysplasia, 
suggesting the possibility of a better outcome following APC ablation 10. However, whether APC 
ablation of intestinal metaplasia reduces the longer term risk of dysplasia and malignancy is still 
uncertain, with no evidence yet reported to support this. In clinical practice APC ablation is falling 
out of favour and is being replaced by RFA in many parts of the world 
 
Radiofrequency ablation (RFA)  
RFA is a newer technique which employs a bipolar array technology to create an electrical field, 
and this generates frictional heating of cellular water. There are currently two devices available, a 
circumferential (HALO360) ablation catheter balloon-based device and an endoscope-mounted 
(HALO90) device. This is a relatively expensive treatment, with the cost of RFA ablation 
consumables varying between A$5,000 and A$8,000 for a full course of treatment, and this has 
limited uptake in Australia and New Zealand. Ablation depth in ex vivo studies has been shown to 
be 0.5 to 1 mm. This correlates with the depth of the muscularis mucosae, and therefore 
“theoretically” might avoid post-ablation stricture formation. As RFA diffusely treats the entire 
epithelium it achieves uniform ablation, and it has been suggested that it minimises the risk of 
buried residual columnar mucosa – “buried glands”. Reported results have generally been good, and 
might be superior to other ablation methods, but follow-up remains short. Fleischer et al reported 
2.5 year follow-up in a multicentre trial involving RFA treatment of Barrett’s oesophagus without 
dysplasia. Complete endoscopic and histopathologic ablation was achieved in 60 of 61 patients 
(complete remission - 98.4%), with no strictures or buried “subsquamous” glands 34. Ganz et al 
reported a multicentre US study that included 142 patients with HGD with a median Barrett’s 
oesophagus segment length of 6 cm. Of 92 patients who had at least one follow-up biopsy, at a 
median of 12 months complete remission of HGD was observed in 90%. However, intestinal 
metaplasia was identified at 46% of follow-up endoscopies 35, suggesting that complete eradication 
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following RFA cannot be reliably predicted. Vaccaro et al reported that the cumulative incidence of 
newly detected intestinal metaplasia at one year after RFA in patients who had complete eradication 
of intestinal metaplasia was 25.9% 36. Vaccaro et al also reported that dysplasia was detected in 
8.5% of the group that had been deemed to have had complete eradication of Barrett’s oesophagus 
at one year follow-up, highlighting the need for continued surveillance after RFA 36. A case of 
squamous cell dysplasia arising in the neosquamous epithelium after RFA for HGD has also been 
reported 17.  
 
Shaheen et al reported a multicentre randomized trial of RFA ablation vs. surveillance for dysplastic 
Barrett’s oesophagus and observed 77% complete regression of intestinal metaplasia following 
RFA vs. 0% for controls at 12 months, as well as complete remission of HGD in 80% of the treated 
group 37. Sub-squamous Barrett’s oesophagus epithelium was found via rigorous biopsy sampling 
in 5.1% of RFA-treated patients at 12 months follow up, versus 25.2% at baseline, and 40% in the 
control group at 12 months. RFA decreased the rate of progression to cancer, although the number 
of cancers in the trial was small (1/84 vs. 4/43; p=0.04) and cancer prevention was not the primary 
end point. More recently Shaheen et al reported 3 year follow-up from the same trial in which 25% 
of patients who initially had dysplasia and had complete eradication of intestinal metaplasia were 
found to have newly detected IM 19. They also reported disease progression in 4.2% of the ablation 
group, and thus concluded that the RFA treated population is still at high-risk, and suggested that 
RFA-treated patients still require ongoing endoscopic monitoring. This study remains the only 
randomized trial evaluating RFA for HGD. It is limited by its relatively short term follow-up, and it 
was funded by the device manufacturer. Other independently funded trials with longer term follow-
up are needed to confirm these results, as well as equivalent cancer control to oesophagectomy. 
 
Endoscopic Mucosal resection 
Endoscopic mucosal resection (EMR) was developed in Japan by Inoue et al for treatment of 
superficial squamous cell carcinomas of the oesophagus 38. This technique is now widely used for 
excisional biopsy of small (less than 2 cm) mucosal irregularities or nodules in patients with 
Barrett’s oesophagus, HGD and intramucosal adenocarcinoma., although several studies on focal 
EMR alone have demonstrated a high rate of synchronous and recurrent lesion development, 
ranging from 14% to 47% 14. EMR also provides a larger and deeper biopsy specimen, allowing 
more precise determination of the depth of tumor penetration than other methods 39. Current data 
support EMR for diagnosis, as a treatment for focal mucosal oesophageal adenocarcinoma, and as 
an adjunct to RFA in the treatment of dysplastic Barrett’s oesophagus epithelium 40. 
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Complete eradication of Barrett’s oesophagus mucosa using EMR has been advocated and 
performed in some centres. However, the risk of complications makes this use more controversial. 
Complete responses have ranged from 76% to 100%, although the complication profile of more 
extensive, circumferential EMR includes stricture formation, with an incidence rate that approaches 
50%, as well as bleeding and oesophageal perforation. In a series of 73 patients, symptomatic 
oesophageal stricture formation was noted in 24.7% of patients undergoing EMR. In multivariate 
analysis stricture formation was associated strongly with resection of >50% of the circumference of 
the oesophagus 41. However, it appears that large non-circumferential EMRs of up to 12 cm2 can be 
performed safely 42. 
 
Gondrie et al combined EMR with RFA to treat patients with HGD or intramucosal cancer. An 
endoscopic and histopathological complete response for intramucosal cancer, dysplasia, and 
intestinal metaplasia was reported for all 12 (100%) patients 43. Furthermore, stricture rates for RFA 
post-EMR appear to be comparable to RFA alone 44.This suggests that EMR might be performed 
with curative intent for tumors at low risk for metastatic spread, and then can be combined with 
mucosal ablation for complete removal of metaplastic or dysplastic oesophageal epithelium to 
prevent further lesion development, although more evidence is needed to support this proposal. 
Again, there is little longer term outcome data to support this approach, and it remains for the 
proponents to demonstrate long term safety and efficacy. This will require larger series from other 
centres, with good longer term follow-up. If good outcomes can be demonstrated, then this 
approach may represent a significant advance for the treatment on HGD and intramucosal cancer. 
 
Ablation outcome vs. method of treatment of gastro-oesophageal reflux   
Treatment of gastro-oesophageal reflux might influence the neoplastic potential of neosquamous 
tissue, and anti-reflux surgery might provide a more stable environment for the maintenance of 
neosquamous epithelium than in patients with reflux managed with PPI’s. The rationale for this 
suggestion is that effective anti-reflux surgery controls both acid and bile reflux, and bile reflux 
appears to be an important factor in the etiology of Barrett’s oesophagus 45. Although PPI therapy 
reduces gastric acid secretion it does not eliminate all acid reflux, nor does it directly control bile 
reflux. In randomised trials of APC ablation reported previously from our Department, at 12 months 
19 of 20 (95%) patients who had undergone ablation following a fundoplication maintained greater 
than 95% Barrett’s oesophagus ablation, whereas in patients managed by PPIs who underwent APC 
ablation, only 14 of 23 (61%) patients maintained this degree of ablation (p = 0.01) 47,48. These 
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findings are consistent with other reports of relatively durable outcomes in post-fundoplication 
patients 29-31, 46 vs. less durable ablation outcomes following APC in patients managed with PPIs 25-
27, 47. How this apparent difference in the stability of neosquamous epithelium affects neoplastic 
potential in the oesophageal mucosa, however, is unknown. 
 
Cost effectiveness of surveillance and endoscopic therapy 
With the outcome for patients presenting with advanced stage oesophageal adenocarcinoma poor, 
regular surveillance endoscopy to detect early neoplasia has been recommended by most of the 
international gastroenterological societies 48. Neoplasias discovered during endoscopic surveillance 
are often curable, and some of these early lesions appear to be suitable for treatment with 
endoscopic therapy. However, surveillance is costly in terms of quality adjusted life years gained18 
and there are difficulties in disease detection as biopsies are generally taken in the absence of a 
visible target lesion within the Barrett’s oesophagus tissue. The rate of progression from Barrett’s 
oesophagus to adenocarcinoma has been reported to range from 0.2 to 2.1% per year, but it is 
probably less than 1% each year 49.  
 
There have been several evaluations of the cost effectiveness of Barrett’s oesophagus surveillance, 
and some have suggested that surveillance might do more harm than good, or is unlikely to be cost-
effective at usual levels of willingness to pay 50-52. However, these studies have been based on 
economic modeling, and the outcomes are specific to both the health care funding model in their 
countries of origin – USA and the UK, and the level of patient and endoscopist compliance. Further, 
these studies have had to rely on a limited evidence base that necessarily contains a large degree of 
uncertainty. Currently, there is evidence that surveillance-detected adenocarcinomas of the 
oesophagus are more likely to be diagnosed at the earlier T1 stage, and therefore have a better 
prognosis than cancers which present with symptoms 53-55. However, there is a lack of evidence that 
surveillance actually improves long term survival in patients undergoing regular endoscopy 
surveillance 56. This is because most patients in a Barrett’s oesophagus surveillance program will 
die of diseases other than oesophageal cancer 57.  
 
If endoscopic ablation reduces cancer incidence, this might be a more cost-effective approach than 
surveillance endoscopy. Modeling studies indicate that ablation might be a good option in patients 
with low grade dysplasia or no dysplasia, but cost effectiveness depends on the long-term 
effectiveness of ablation (prevention of cancer) and whether surveillance endoscopy can be 
discontinued after successful ablation58, 59. This modeling suggests that if ablation can permanently 
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eradicate non-dysplastic metaplasia in at least 40% of patients, and avoid the need for ongoing 
endoscopy, ablation would be preferred to surveillance 59. In a threshold analysis, the critical 
determinants of the cost-effectiveness of ablation were the response to ablation, total cost of 
ablation, and risk of progression to dysplasia 58. Cost and response are relatively straightforward to 
assess. However, the risk of progression is inherently difficult to ascertain due to the low rate of 
progression from Barrett’s oesophagus. For the end point of cancer prevention to be investigated in 
randomized trials, these would need to be multi-centre to recruit a sufficient number of patients, and 
would require a long period of follow-up. Such studies might be facilitated with the addition of 
biomarkers. For now health economic modeling is the most efficient way to address these 
questions, although the reliability of any model is only as good as the data which underpins it. 
Larger patterns of care studies are needed to inform such work.  
 
Biomarker use in Endoscopic Surveillance 
Surveillance outcomes and cost-effectiveness might be improved through the identification and use 
of appropriate biomarkers to identify risk of progression to cancer, and thereby direct surveillance 
efforts specifically at high risk individuals. Inadomi et al identified that the use of a biomarker or a 
panel of biomarkers, whose sensitivity and specificity to predict cancer development exceeded 
80%, could be a more viable strategy than dysplasia-based surveillance, and overcome the inherent 
inter- and intra-observer variations in dysplasia diagnosis that currently limit the effectiveness of 
surveillance programs 51. Furthermore, with the potentially improved cost-effectiveness of bio-
marker based surveillance combined with endoscopic therapy for early cancer, targeted population 
screening may also become cost-effective. 
 
However, biomarker development has proved challenging as oesophageal adenocarcinoma is a 
heterogeneous disease 60, 61. Phenotypic and genotypic heterogeneity have also been observed in 
Barrett’s oesophagus epithelium 62, 63. This is highlighted by the observation that genetic clonal 
diversity in Barrett’s epithelium is associated with progression to adenocarcinoma 61. It has 
therefore not yet been possible to develop a panel of biomarkers to meet the requirements indicated 
by the study of Inadomi et al 51. For example, the combination of 17p LOH, 9pLOH, and 
aneuploidy/tetraploidy has been shown to have a sensitivity for predicting cancer development of 
59% at 10 years follow-up in a high risk population 64. In a blinded multi centre study, a panel of 8 
DNA methylation based biomarkers had a sensitivity for cancer prediction of 60% at 4 years when 
modeled against an 80% specificity 65.  
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The problem of genotypic heterogeneity has clearly limited the use of biomarkers in this disease, 
but it may be feasible to utilize biomarkers with sensitivity and specificity lower than 80% if 
endoscopic ablation techniques become sufficiently effective at preventing disease progression to 
allow lengthening of surveillance intervals, or to allow replacement of endoscopic surveillance with 
non-endoscopic forms of surveillance 59. 
 
Molecular biology studies assessing the normality of neo-squamous mucosa  
Although ablation of Barrett’s oesophagus produces a neosquamous epithelium, there have been 
reports of oesophageal adenocarcinoma developing after ablation 66, 67. Incomplete ablation and/or 
residual metaplastic glands under an apparently normal looking neosquamous epithelium may be 
responsible for post ablation neoplasia. Consistent with this are reports that recurrent and/or 
persistent Barrett’s oesophagus after ablation therapy contains genetic alterations associated with 
malignancy 68. In some patients the neosquamous epithelium that regenerates following ablation 
may harbor genetic abnormalities. Paulson et al reported a patient (1 of 20) that had a p16 deletion 
in an island of neosquamous epithelium after ablation that was identical to that seen in the Barrett’s 
epithelium 69. Lopes et al found that those patients who expressed p53 in their metaplastic mucosa 
were subsequently found to express p53 in their neosquamous epithelium after APC ablation 70. 
These reports suggest that neosquamous mucosa is abnormal in some patients after ablation. 
  
Two recent studies have investigated the genetic normality of the neosquamous mucosa after RFA. 
Pouw et al reported normalization of Ki-67 and p53 protein expression measured by 
immunohistochemistry, and of chromosomal abnormalities involving chromosomes 1 and 9 and the 
loci for the tumour suppressor genes p16 and p53 for 22 patients with Barrett’s oesophagus 
containing early cancer and/or high-grade intraepithelial neoplasia 71. The results of this study 
suggest that RFA may produce a more normalized neosquamous epithelium than PDT or APC 
ablation. However, the molecular heterogeneity of this disease does not allow us to draw firm 
conclusions. Pouw et al acknowledged this by stating that they did not evaluate other molecular 
changes which might be important in this disease such as the specific mutational status of other 
genes such as p53 or p16, loss of heterozygosity (LOH), or alterations in protein expression. 
Galipeau et al reported that 80% of patients with aneuploidy, p53 LOH, and p16 LOH developed 
cancer at 6 years 64, so these biomarkers may also need to be evaluated in patients treated with 
RFA. However, 12% of patients that did not have any of these specific markers also developed 
cancer within 10 years, suggesting that the approach of using specific biomarkers might be limited 
by molecular heterogeneity and the broad range of potential lesions.  
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Post-ablation abnormalities may occur if some pre-malignant lesions are resistant to ablation. For 
example, p16 allelic loss has been reported to be associated with a decreased response to ablation 72. 
This type of lesion may reside in stem cells and/or occult columnar tissue (islands or buried), and its 
presence could potentially be detected in neo-squamous mucosa either directly, or as a field effect. 
In support of this, we have previously reported that the Barrett’s oesophagus associated microRNA, 
miR-143, is expressed at higher levels in post-APC ablation neo-squamous mucosa in some 
patients, and in pre-ablation proximal squamous tissue above Barrett’s oesophagus, compared to the 
squamous oesophageal mucosa of healthy patients 73. Whether this is due to the presence of ablation 
resistant stem cells and/or residual occult columnar tissue, or from a field effect, is unknown. The 
possibility that neo-squamous tissue may not be normal in some patients suggests the need for 
surveillance following ablation, and for further studies which compare the molecular profile of 
neosquamous epithelium with normal squamous epithelium. Although neosquamous epithelium has 
been shown to occasionally retain some markers associated with Barrett’s oesophagus epithelium, it 
may also differ from normal squamous epithelium in the expression of unsuspected but important 
genes.  
 
Conclusions 
Endoscopic ablation has been introduced into clinical practice largely without formal evaluation, 
and it is not certain that this has improved any clinical outcomes. Due to the use of endoscopy 
facilities and consumables, ablation is associated with significant cost, and this has limited the 
uptake of RFA in particular in some parts of the world, including Australia and New Zealand. 
Hence, determining whether ablation reduces the risk of cancer sufficiently in Barrett’s oesophagus 
and whether ablation can be cost-effective, is important.  
 
To date there have been no randomized trials comparing endoscopic therapies with surgery for early 
stage oesophageal cancers 74, although studies to date suggest that endoscopic therapies produce 
increased survival at 4 years for oesophageal cancers compared to no therapy 75 and population 
based data suggests that patients with early oesophageal cancer managed with endoscopic therapy 
have equivalent long-term survival compared to those treated with surgical resection 76. However, 
despite these encouraging observations, intensive surveillance is still required after endoscopic 
therapy, and this brings into question the cost-effectiveness of all of the new endoscopy based 
strategies. Studies are required to better determine the effectiveness of ablation strategies for 
Barrett's oesophagus at both the clinical and the cellular level, and such studies should also 
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investigate whether the method of reflux control impacts on outcomes. Good efficacy at long term 
follow-up, in large patient cohorts should be demonstrated. Until such studies are reported, patients 
should remain on close endoscopic follow-up, and outcomes should be carefully audited. 
Nevertheless, if in the future, high quality evidence confirms that ablation is an effective alternative 
to surgical oesophagectomy in patients with HGD or intramucosal cancer, endoscopic treatment 
might replace oesophagectomy for early stage disease. For now, it is likely we are in transition to a 
new clinical paradigm. Oesophageal surgeons need to be actively engaged in the development, 
assessment and implementation of these new techniques. 
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